๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Luoyang
Clinical trial register · China

Clinical Trials in Luoyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 60 Guangzhou 46 Chengdu 43 Changsha 36 Chongqing 29
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing60 Guangzhou46 Chengdu43 Changsha36 Chongqing29
All 76 locations
Target enrolment
to

Trials with a site in Luoyang

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Changde, Guangzhou, Hangzhou, Jiangmen, Luoyang
2025-11-28
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/luoyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Luoyang that also match the filters currently applied.

How many clinical trials are recruiting in Luoyang?

3 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Luoyang), 5 studies
PhaseStudiesRecruitingShare
Phase 22240%
Phase 32140%
Phase 2/31020%

Most active sponsors

Lead sponsors with the most studies (Luoyang)
Lead sponsorStudiesRecruiting
Eli Lilly and Company53
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.